

AstraZeneca Pharma India Limited  
 Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045  
 Statement of unaudited results for the quarter and nine months ended 31 December 2017

| SI No. | Particulars   | Rs in lakhs                                 |   |   |   |   |
|--------|---|---|---|---|---|---|
|        |   | 3 months ended<br>31/12/2017<br>(Unaudited) | 3 months ended<br>30/09/2017<br>(Unaudited) | 3 months ended<br>31/12/2016<br>(Unaudited) | 9 months ended<br>31/12/2017<br>(Unaudited) | 9 months ended<br>31/12/2016<br>(Unaudited) |
| 1      | <b>Revenue</b>  |   |   |   |   |   |
|        | a) Revenue from operations  | 12,853.86                                   | 16,425.83                                   | 15,150.22                                   | 42,126.27                                   | 43,177.37                                   |
|        | b) Other income   | 275.97                                      | 249.57                                      | 989.77                                      | 990.94                                      | 1,339.74                                    |
|        | <b>Total revenue</b>  | <b>13,129.83</b>                            | <b>16,675.40</b>                            | <b>16,139.99</b>                            | <b>43,117.21</b>                            | <b>44,517.11</b>                            |
| 2      | <b>Expenses</b>   |   |   |   |   |   |
|        | (a) Cost of materials consumed  | 778.78                                      | 312.40                                      | 244.49                                      | 1,638.94                                    | 870.04                                      |
|        | (b) Purchase of stock-in-trade  | 7,326.39                                    | 4,778.19                                    | 3,561.85                                    | 17,948.54                                   | 11,394.42                                   |
|        | (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | (4,260.83)                                  | 254.76                                      | 893.09                                      | (5,883.26)                                  | 1,319.11                                    |
|        | (d) Excise duty   | -   | -   | 121.61                                      | 98.50                                       | 378.13                                      |
|        | (e) Employee benefits expense   | 3,711.65                                    | 3,640.19                                    | 3,774.48                                    | 10,845.72                                   | 12,551.07                                   |
|        | (f) Depreciation and amortisation expense   | 373.01                                      | 374.85                                      | 401.92                                      | 1,118.66                                    | 1,215.10                                    |
|        | (g) Selling, marketing and distribution expense                                   | 2,456.81                                    | 1,526.49                                    | 1,861.29                                    | 5,169.21                                    | 4,564.88                                    |
|        | (h) Other expenses  | 3,925.63                                    | 2,348.84                                    | 3,181.04                                    | 9,206.54                                    | 8,475.07                                    |
|        | (i) Finance cost  | -   | -   | -   | -   | -   |
|        | <b>Total expenses</b>   | <b>14,311.44</b>                            | <b>13,235.72</b>                            | <b>14,039.77</b>                            | <b>40,142.85</b>                            | <b>40,767.82</b>                            |
| 3      | <b>(Loss)/ Profit before exceptional and extraordinary items and tax (1-2)</b>    | <b>(1,181.61)</b>                           | <b>3,439.68</b>                             | <b>2,100.22</b>                             | <b>2,974.36</b>                             | <b>3,749.29</b>                             |
| 4      | Exceptional items   | -   | -   | -   | -   | -   |
| 5      | <b>(Loss)/ Profit before extraordinary items and tax (3+4)</b>                    | <b>(1,181.61)</b>                           | <b>3,439.68</b>                             | <b>2,100.22</b>                             | <b>2,974.36</b>                             | <b>3,749.29</b>                             |
| 6      | Extraordinary items   | -   | -   | -   | -   | -   |
| 7      | <b>(Loss)/ Profit before tax (5+6)</b>  | <b>(1,181.61)</b>                           | <b>3,439.68</b>                             | <b>2,100.22</b>                             | <b>2,974.36</b>                             | <b>3,749.29</b>                             |
| 8      | <b>Tax expense</b>  |   |   |   |   |   |
|        | - Current tax   | (146.39)                                    | 698.77                                      | 479.18                                      | 704.99                                      | 787.85                                      |
|        | - Deferred tax  | -   | 2.43  | -   | -   | -   |
|        | <b>Total tax expense</b>  | <b>(146.39)</b>                             | <b>701.20</b>                               | <b>479.18</b>                               | <b>704.99</b>                               | <b>787.85</b>                               |
| 9      | <b>(Loss)/ Profit for the period (7-8)</b>  | <b>(1,035.22)</b>                           | <b>2,738.48</b>                             | <b>1,621.04</b>                             | <b>2,269.37</b>                             | <b>2,961.44</b>                             |
| 10     | <b>Other comprehensive income, net of income tax</b>                              |   |   |   |   |   |
|        | A. Items that will not be reclassified to profit or loss                          | 243.27                                      | (9.43)                                      | (58.59)                                     | 282.60                                      | (213.13)                                    |
|        | B. Items that will be reclassified to profit or loss                              | -   | -   | -   | -   | -   |
|        | <b>Total other comprehensive income, net of income tax</b>                        | <b>243.27</b>                               | <b>(9.43)</b>                               | <b>(58.59)</b>                              | <b>282.60</b>                               | <b>(213.13)</b>                             |
|        | <b>Total comprehensive income for the period (9+10)</b>                           | <b>(791.95)</b>                             | <b>2,729.05</b>                             | <b>1,562.45</b>                             | <b>2,551.97</b>                             | <b>2,748.31</b>                             |
| 11     | <b>Paid-up equity share capital</b><br>(Face value of Rs 2/- per equity share)    | <b>500.00</b>                               | <b>500.00</b>                               | <b>500.00</b>                               | <b>500.00</b>                               | <b>500.00</b>                               |
| 12     | <b>Earnings per equity share of Rs 2/- each (basic and diluted)</b>               | <b>(4.14)</b>                               | <b>10.95</b>                                | <b>6.48</b>                                 | <b>9.08</b>                                 | <b>11.85</b>                                |



AstraZeneca Pharma India Limited

Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045

Statement of unaudited results for the quarter and nine months ended 31 December 2017

Notes:

- 1 The above statement of results has been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 5 February 2018. The statutory auditors of the Company have carried out a limited review of this statement of results for the quarter ended 31 December 2017.
- 2 This Statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning 1 April 2017, the Company has for the first time adopted Ind AS with a transition date of 1 April 2016.
- 3 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly no segment information has been provided.
- 4 As previously disclosed, by way of a letter dated 1 March 2014, AstraZeneca Pharmaceuticals AB, the promoter of the Company had proposed a voluntary delisting of the Company's equity shares from the National Stock Exchange and the Bombay Stock Exchange. Such proposed delisting is subject to an on-going inquiry with SEBI and that inquiry has not yet been resolved. In any event, based on the passage of time, any potential future proposal for voluntary delisting of the Company would need to be conducted de novo.
- 5 The Statement does not include Ind AS compliant statement of results for the previous year ended 31 March 2017 as the same is not mandatory as per SEBI's circular dated 5 July 2016.
- 6 Previous period's figures have been regrouped to conform with the current period's presentation for the purpose of comparability.
- 7 The reconciliation of net profit reported in accordance with Indian GAAP to total comprehensive income in accordance with Ind AS is given below:

| Particulars   | 3 months ended<br>31/12/2016 | 9 months ended<br>31/12/2016 |
|---|------------------------------|------------------------------|
| <b>(a) Net Profit as per previous GAAP (Indian GAAP)</b>  | 1,596.29                     | 2,731.76                     |
| Add/ (less): Adjustment for Ind AS  |                              |                              |
| Impact on provision of expected credit loss   | (33.27)                      | (27.59)                      |
| Reversal of rent equalisation reserve   | 6.33                         | 18.98                        |
| Reclassification of net actuarial (gain)/loss on defined benefit plan to other comprehensive income | 58.59                        | 213.13                       |
| Impact of Employee stock compensation plan  | (19.40)                      | (18.57)                      |
| Others*   | 12.50                        | 43.75                        |
| <b>(b) Net profit after tax as per Ind AS</b>   | <b>1,621.04</b>              | <b>2,961.44</b>              |
| <b>(c) Other comprehensive income net of income tax:</b>  |                              |                              |
| Actuarial loss on defined benefit plan  | (58.59)                      | (213.13)                     |
| <b>(d) Total comprehensive income under Ind AS (b+c)</b>  | <b>1,562.45</b>              | <b>2,748.31</b>              |

\* Others mainly include adjustments on account of discounting of non-current security deposits, employee loans, fair value adjustment on equity investments etc.

By Order of the Board of Directors  
For AstraZeneca Pharma India Limited



Rajesh Marwaha  
Chief Financial Officer & Director

Place: Bengaluru  
Date: February 05, 2018

